Windtree Therapeutics(WINT) - 2021 Q2 - Quarterly Report

Table of Contents For the transition period from _____ to _____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Commission file number 000-26422 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Windtree Therapeutics, Inc. For the quarterly period ended June 30, 2021 (Exact name of registrant as specified in its charter) or Delaware (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SECTION ...